n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine has been researched along with dihydroergocristine monomesylate in 2 studies
| Studies (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Trials (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Recent Studies (post-2010) (n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine) | Studies (dihydroergocristine monomesylate) | Trials (dihydroergocristine monomesylate) | Recent Studies (post-2010) (dihydroergocristine monomesylate) |
|---|---|---|---|---|---|
| 79 | 1 | 16 | 13 | 0 | 4 |
| Protein | Taxonomy | n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine (IC50) | dihydroergocristine monomesylate (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.239 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 3 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.002 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 3 | |
| Beta-3 adrenergic receptor | Homo sapiens (human) | 3.308 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0015 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0079 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0087 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.0007 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.179 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.0074 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.239 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.0007 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.85 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.0023 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.0066 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.042 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
2 other study(ies) available for n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine and dihydroergocristine monomesylate
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |